ziftomenib: mechanism of action and promising results in patients with kmt2ar or npm1m aml
Published 1 year ago • 202 plays • Length 3:17Download video MP4
Download video MP3
Similar videos
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:38
lba: komet-001 - ziftomenib monotherapy in r/r npm1-mutated aml
-
2:00
the incorporation of immunotherapy into frontline all treatment
-
2:51
komet-008: a phase i trial of ziftomenib combinations in kmt2a-rearranged or npm1-mutant aml
-
1:14
promising novel agents in aml: menin inhibitors
-
4:04
the future of myeloma treatment and the possibility of cure
-
9:25
mgus diagnosis: a step-by-step approach
-
7:46
updates in aml treatment and research from asco 2023
-
3:55
ziftomenib: a menin inhibitor for r/r npm1-mutated aml
-
1:39
the mechanism of action of navtemadlin and its role in mf
-
3:46
update on komet-001: identifying the optimal dose of ziftomenib for patients with r/r aml
-
1:12
phase i study of ziftomenib with venetoclax or venetoclax/azacitidine or 7 3 in r/r aml
-
1:24
mechanisms of resistance to flt3 inhibitors in aml and strategies to overcome this
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
2:09
advances in the management of fit adults with aml
-
1:09
menin inhibitors for the treatment of aml: insights into the covalent-101 trial
-
4:22
the role of mrd in aml
-
1:37
a phase ii trial evaluating e7820 in patients with aml with splicing factor mutations
-
1:02
a phase ii single-arm study of obinutuzumab plus ibrutinib as frontline treatment for fl and mzl
-
1:51
thrombotic and bleeding complications in al amyloidosis
-
1:30
a phase i trial investigating a novel oral flt3 inhibitor, bmf-500, in flt3-mutant aml